# Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

> **NCT01516424** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma (Suzhou) Co., Ltd.** · enrollment: 267 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Blonanserin
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01516424
- **Lead sponsor:** Sumitomo Pharma (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516424, "Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01516424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*